Inactive Instrument

Imprimis Pharmaceuticals Inc Stock Nasdaq

US45323A2015

Chart Imprimis Pharmaceuticals Inc

Duration

Period

Style

Dynamic Chart

Latest news about Imprimis Pharmaceuticals Inc

Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
Top Midday Decliners	Mar. 20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow, Inc. Announces Board of Director Appointments	Jan. 29	CI
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	Jan. 03	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03	MT

More news

Latest transcript on Imprimis Pharmaceuticals Inc

Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024

Mar. 20

More transcripts

Analyst Recommendations on Imprimis Pharmaceuticals Inc

Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating	Nov. 14	MT
B. Riley Raises Harrow Health's PT to $45 From $42 on Heels of Announced Transactions With Santen, Novaliq; Keeps Buy Rating	23-07-20	MT
B. Riley Raises Harrow Health's Price Target to $42 From $24, Keeps Buy Rating	23-05-04	MT

More recommendations

Press releases Imprimis Pharmaceuticals Inc

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	Apr. 03	AQ
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	Mar. 20	AQ
Harrow : Q4-2023 Letter to Stockholders	Mar. 19	PU
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results after Market Close on March 19, 2024	Mar. 06	AQ
Harrow Announces New Appointments to its Board of Directors	Jan. 30	AQ

More press releases

News in other languages on Imprimis Pharmaceuticals Inc

LATE BRIEFING - Unternehmen und Märkte -2-	22-12-14
Harrow Health erwirbt US-Rechte an fünf Novartis-Augenmitteln	22-12-14
Novartis gibt US-Vertriebsrechte für Augenarzneien an Harrow ab	22-12-14

More news

Managers and Directors - Imprimis Pharmaceuticals Inc

Managers	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	05-12-31
Andrew Boll DFI	Director of Finance/CFO	41	11-11-30
Jamie Webb IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	05-12-31
Lauren Silvernail BRD	Director/Board Member	65	Jan. 25
Adrienne Graves BRD	Director/Board Member	69	Jan. 25

More insiders

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

Sales 2024 *	185M	Sales 2025 *	251M	Capitalization	363M
Net income 2024 *	-12M	Net income 2025 *	23M	EV / Sales 2024 *	1.97 x
Net cash position 2024 *	-	Net cash position 2025 *	-	EV / Sales 2025 *	1.44 x
P/E ratio 2024 *	-31.8 x	P/E ratio 2025 *	17.3 x	Employees	-
Yield 2024 *	-	Yield 2025 *	-	Free-Float	85.41%